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A B S T R A C T
Nanoparticles have the potential to modulate both the pharmacokinetic and pharmacodynamic profiles of
drugs, thereby enhancing their therapeutic effect. The versatility of nanoparticles allows for a wide range of
customization possibilities. However, it also leads to a rich design space which is difficult to investigate and
optimize. An additional problem emerges when they are applied to cancer treatment. A heterogeneous and
highly adaptable tumour can quickly become resistant to primary therapy, making it inefficient. To automate
the design of potential therapies for such complex cases, we propose a computational model for fast, novelty-
based machine learning exploration of the nanoparticle design space. In this paper, we present an evolvable,
open-ended agent-based model, where the exploration of an initially small portion of the given state space
can be expanded by an ongoing generation of adaptive novelties, whenever the simulated tumour makes
an adaptive leap. We demonstrate that the nano-agents can continuously reshape themselves and create a
heterogeneous population of specialized groups of individuals optimized for tracking and killing different
phenotypes of cancer cells. In the conclusion, we outline further development steps so this model could be
used in real-world research and clinical practice.1. Introduction
Malignant tumours are heterogeneous structures that can rapidly
acquire drug resistance (Holohan et al., 2013). Therapies can lead to
substantial regressions but the effect is often short-lived and cancer
evolves to become resistant within a few months (Shaffer et al., 2017;
Bozic et al., 2013). Resistance can arise via two main mechanisms: (i)
selection of pre-existing resistant cells and (ii) the emergence of resis-
tant cancer cells that continue to evolve under selective pressure (Hu
et al., 2017). To overcome therapy resistance, clinical practices are
using the recently emerging approach of combinatorial therapy — com-
bining multiple drugs in order to synergistically eliminate the various
clones that emerge in a tumour (Chen and Lahav, 2016). However,
the problem remains how to properly design combinatorial therapy:
which drugs to choose, whether they should be applied sequentially
or simultaneously, appropriate time intervals between treatments, and
the correct concentration of each drug. Choosing the appropriate target
is an additional issue. Recent studies have shown that phenomena such
as drug resistance and metastasis are sustained due to so-called cancer
stem cells (CSCs) (Pattabiraman and Weinberg, 2014). These cells
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represent a small subpopulation of cancer cells that have an unlimited
capacity for self-renewal, differentiation, and tumourigenesis. More-
over, they are insensitive to most of the conventional therapies, and the
percentage of CSCs within a tumour often increases after chemother-
apy (Kurtova et al., 2014). Finally, in designing optimal therapies, the
drug’s side effects should also be considered (Fanciullino et al., 2013).
The use of nanoparticles (NP) as drug carriers can overcome the
limitations associated with traditional drug therapy. Due to the ver-
satility of nanoparticles and possibilities of customization, they can
improve site-specific targeting of drugs, increase in vivo stability, ex-
tend the drug’s blood circulation time, and allow for controlled drug
release (Maeda et al., 2013; Blanco et al., 2015; Wicki et al., 2015).
However, despite potentially high benefits, state-of-the-art NP-based
cancer treatments have not shown the expected efficacy, in part due
to the lack of detailed knowledge of the behaviour of NP-drug com-
plexes (Wilhelm et al., 2016). Therefore, there has been a lot of focus
on the use of computational models for improving NP design (Rockne
et al., 2019). However, simulations have mostly considered only certain
tumour scenarios and have disregard other crucial aspects of treatmentvailable online 17 November 2020
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of various cell subpopulations: sensitive and resistant cells, prolif-
erating, quiescent cells and CSC) is taken into consideration when
modelling tumour growth, most models do not take this into account
when modelling tumour treatments. Various cells can respond differ-
ently to therapy and, hence, can influence nanoparticle design (Karev
et al., 2006). The accumulation of nanoparticles at effective doses in
cancer cells is also not considered (Hauert et al., 2013).
In summary, in order to design an efficient treatment tailored to a
specific tumour, we are facing an immense state-space generated by:
(i) various drugs for targeting specific cancer cells, (ii) NPs that can
modify physicochemical properties of those drugs, (iii) heterogeneous
and highly adaptable tumour that can quickly become resistant to
the primary therapy, and (iv) treatment specific details, such as the
concentration and dose schedule. While models can certainly help us
make informed decisions, computationally testing all possibilities is in-
tractable. It has been demonstrated that both Gaussian process models
and multi-layer perceptron neural network models are able to effec-
tively explore the parameter-space of bio-physical tumour properties
in order to find the optimal therapeutic strategy (Preen et al., 2019).
However, that work has investigated the effect of NPs on homogeneous,
static tumours that cannot evolve. To automate the creation of therapies
for more realistic cases, we need a more open-ended approach where
the exploration of an initially small portion of the given state space can
be expanded by an ongoing generation of adaptive novelties, whenever
the simulated tumour makes the adaptive leap (see the Model architec-
ture for further details). An initial attempt towards the implementation
of open-ended approaches was made by utilizing the novelty search
method (Tsompanas et al., 2020), however, once again a homogeneous,
static type of tumour was studied.
To demonstrate the basic implementation of, what Taylor (2019)
would classify as an exploratory open-ended evolutionary model, we
created a simple engine for the virtual evolution of combinatorial
oncological treatments. It is a system of non-interacting evolvable
nano-agents in the environment of cancer- and healthy-cells. Since
the tumour can adapt and, thus, become resistant to nano-agents, the
adaptive landscape of nano-agents is under constant modification so the
context in which their evolution occurs is continuously changing. As a
result, the population of nano-agents reshapes itself and creates a het-
erogeneous population of specialized groups of individuals optimized
for tracking and killing different phenotypes of cancer cells.
2. Model architecture and simulation settings
We use Mesa, an agent-based modelling platform for Python (Masad
and Kazil, 2015). Complete source code of the model is available at
https://github.com/yotf/CancerModel/. The world is non-toroidal 2D
grid populated with three types of cell-agents (cancer cells — CC;
cancer stem cells — CSC; healthy cells — HC) and nano-agents — NA.
Multiple agents can occupy the same location in the grid.
Cell-agents: All cell-agents are unmovable. CC and CSC can mutate
with some small probability (see Simulation Setting). By mutating
they change their ‘‘visible’’ properties through which nano-agents can
recognize them. The tumour can grow through the division of CC
and CSC. In scenarios with the growing tumour, after each time step,
tumour cells divide with a certain probability (termed ‘‘growth rate’’ in
the following) if there are unoccupied grid locations in their immediate
neighbourhood. Healthy cells (HC) can be killed, but do not mutate or
grow.
Nano-agents: The nano-agents can move, attack, observe and mem-
orize their environment. They can have two kinds of behaviour. They
can either try to kill cell-agents or inhibit their division and the quantity
of each agent type is determined at the beginning of the simulation (see
Table 1). At the beginning of the simulation, NA’s knowledge of the
environment is blank so they do not recognize any type of cell-agents.
Movement : At each time step each nano-agent moves randomly into its2
p
Fig. 1. State diagram describing behaviour of a nano-agent after recognizing a cancer
cell. 𝑝𝑎: probability of binding to a cell; 𝑝𝑑 : probability of disassociation from a cell;
𝑝𝑖: probability of internalization into a cell.
Moore neighbourhood. The speed parameter 𝑠 determines how far it
can go. Observing & learning : After moving, the nano-agent observes its
environment, which, in this version, is restricted only to the grid cell
that the nano-agent landed on. By observing, the nano-agent checks the
visible properties of the cell-agent with whom it shares the grid location
and compares them with those stored in the nano-agent’s memory. If
it encounters an unknown cell-agent, it memorizes its properties. The
memory is finite and its size is randomly chosen in the range 0−3 (e.g. if
memory size is 3 it allows storage of up to three visible properties). If
memory is full, new information pushes out the oldest existing one.
Attacking tumour and healthy cells: When a NA is in the same loca-
tion, it goes through a series of states described in Fig. 1. The NA will
attempt to kill or inhibit the division of a cell only if it gets internalized
into that cell (for the probabilities of association (𝑝𝑎), disassociation
(𝑝𝑑) and internalization (𝑝𝑖) see Table 1). Since the goal is to virtually
evolve potential treatment strategies, after trying to attack the cell, NAs
do not perish but continue with movement in the next time step. To
discriminate relative importance of cells, NA gets +1 point for killing
or stopping the division of CC, −1 point for HC and +5 for CSC. If the
NA encounter already memorized cell-agent, the probability of binding
is defined by 𝑝𝑎. Otherwise, the probability of binding is reduced by
multiplying 𝑝𝑎 with the factor 𝑐. Through the factor 𝑐, we can fine-tune
the ‘‘curiosity’’ of NAs in exploring the environment.
Tumour resistance: Randomly chosen subpopulation of tumour cells
is partially resistant to NAs, by adding resistance modifiers to them. The
default size of the resistant sub-population is 10% of the total number of
tumour cells. Upon interacting with NAs, resistant cell can modify one
of the following NA’s properties: binding (𝑝𝑎), disassociation (𝑝𝑑), in-
ternalization (𝑝𝑖), killing (𝑝𝑘) and inhibition of division (𝑝𝑠𝑑). The exact
property to which each cell-agent is resistant is randomly determined
at the beginning of the simulation. Resistance strength is randomly
chosen in the interval 30 − 80%. This means that upon the interaction
between a resistant cell and a nano-agent, a corresponding property
of a nano-agent is reduced by the chosen percentage. If cells divide,
resistance is passed on to the next generation. All CSC are partially
resistant to killing and inhibition of division, by randomly choosing
resistance strength in the interval 50 − 80%, at the beginning of the
simulation.
Evolution of nano-agents: When a NA kills a cell-agent it is assigned
ositive or negative points (described above). The performance of each
BioSystems 199 (2021) 104290I. Balaz et al.
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Table 1
Simulation parameters. 𝑝𝑎 - probability of association; 𝑝𝑑 - probability of disassociation;
𝑝𝑖 - probability of internalization; 𝑝𝑘 - probability of killing; 𝑝𝑠𝑑 - probability of stopping
cell division.
Description Value
Grid size 35𝑥35
Initial number of cancer cells 297
Initial number of cancer stem cells 3
Initial number of healthy cells 925
Size of nano-agent population 500
CC and CSC mutation probability 0.1
CC and CSC growth rates 0.01, 0.005, 0.001
Curiosity (𝑐) 0.5
Detachment (𝑑) 10%
Number of injection sites (𝑛) 5
Speed range 1 − 5
𝑝𝑎, 𝑝𝑑 , 𝑝𝑖, 𝑝𝑘, 𝑝𝑠𝑑 of NA𝐺 that attack CC 0.7, 0.5, 0.7, 0.7, 0.7
𝑝𝑎, 𝑝𝑑 , 𝑝𝑖, 𝑝𝑘, 𝑝𝑠𝑑 of NA𝐺 that attack HC 0.5, 0.5, 0.5, 0.5, 0.5
NA is measured after 10 time steps by comparing collected points.
ive percent of top performers are duplicated and the same percent
f worst performers are eliminated; hence, the population size of NAs
emains constant. Middle five percent of remaining NAs are mutated.
utable properties are speed, memory size, probabilities of association,
isassociation, and internalization, as well as behaviour (inhibit cell
ivision or kill a cell). To compare different simulation runs we defined
he overall fitness function as 𝑓 (𝑁𝐴) = ∑𝐻𝐶∕(𝑟∑𝐶𝑆𝐶+∑𝐶𝐶) where
𝑟 = 5 is the relative importance, that gives advantage to NAs who killed
CSCs.
Metastasis: Since CSC drive the metastasis (Gener et al., 2016)
we implemented a simplified measure of metastasis as an additional
numeric property the ‘‘detachment’’ 𝑑 of a CSC agent. At each step, the
CSC will leave the tumour with 10% probability. If the CSC leaves, the
metastasis score is incremented by 1.
Simulation Settings: Since the two main goals of experiments in this
manuscript are to test (i) whether, and to what extent, NAs are capable
of dealing with an evolvable tumour, and (ii) whether spontaneously
evolved combinatorial therapy can be more efficient than generalized
therapy, we created three classes of NAs:
• NA0 agents that cannot learn. They can only recognize and attack
initial (non-mutated) tumour cells. If the tumour cells mutate they
become invisible to NA0. A real-life equivalent is treatment with
single anti-cancer drugs that are specialized for a certain tumour
type;
• NA𝐸 fully evolvable agents;
• NA𝐺 agents that attack all cells, both healthy and tumour, with
a slight bias towards tumour cells (See Table 1). A real-life
equivalent of this is treatment with cytostatic drugs;
To represent a release of nanoparticles through the bloodstream,
NAs are injected at 𝑛 randomly chosen locations in the grid. After in-
jection agents disperse through the grid space, at the speed determined
by 𝑠.
In order to determine how many experimental runs (denoted as
𝑒∗) are necessary to mitigate the uncertainty that stems from model
stochasticity, we first performed a Consistency Analysis. Detailed
methodology is described elsewhere (Alden et al., 2013; Read et al.,
2012). In short, we analysed sample sizes of 1, 5, 50, 100, 150, 200 and
300 in silico runs. For each sample size we created 20 groups of
distributions, all generated using the same fixed set of parameter
values and containing identical numbers of simulation samples. So,
for example, sample size of 100, each of the 20 groups of distributions
contains Fitness function results of 100 runs (which gives a total of 2000
runs). Then, to compare distributions within one group, we employ a
non-parametric effect magnitude test based on the Vargha–Delaney Â3
test (Vargha and Delaney, 2000). The Â test compares two populationdistributions and returns a value in the range [0.0,1.0] that represents
the probability that a randomly chosen sample taken from population
A is larger than a randomly chosen sample from population B. A value
of 0.5 indicates no difference at all, whereas values above 0.71 indicate
a ‘‘large’’ difference in the distributions. As an acceptable level for
‘‘small’’ difference, we used 0.56. The minimal sample size where maxÂ
value is below 0.56 for all tested run durations (up to 1000 steps) and
for both scenarios (static and growing tumour) is 𝑒∗ = 200 (Fig. 2).
Therefore, all results shown below represent an average of 200 runs.
3. Simulation results and discussion
Non-evolvable, homogeneous tumour.
To test the basic dynamics of nano-agents, we first simulated their
behaviour in the most simple tumour scenario: non-evolvable homo-
geneous tumour. Here, cancer cells cannot mutate and do not have
resistance modifiers. In combination with NA0 agents this constitutes
the minimal setting of our model. In such scenario, fully evolvable
NA𝐸 agents and non-evolvable NA0 agents behave identically (Fig. 3a).
They eliminate the entire tumour and reach the fitness peak in the
first 500 time steps. NA𝐺 agents are the worst-performing. Even though
they manage to kill the tumour, in the process they also kill all the
healthy cells. Given the high incentive to eliminate CSC (defined by the
fitness function) and the low CSC number, all three types of nano-agents
eliminate the entire CSC population within the first 40–60 generations,
so the metastatic score remains low.
Although the results seem promising, this tumour scenario is highly
unrealistic. Real tumours are not homogeneous masses of identical
cells. In fact, the main limiting factor in treating cancer patients is drug
resistance, that stems from tumour heterogeneity (Vasan et al., 2019).
Tumour resistance can be divided into two categories: the intrinsic
resistance (as a result of pre-existing resistant cells in a tumour, before
drug treatment) and the acquired resistance (developed during or after
therapy either by genetic changes in a tumour microenvironment).
Therefore, in the following section, we investigate to what extent the
open-ended evolution of nano-agents can deal with both categories of
resistance.
Tumour drug resistance and exploratory open-endedness of NAs.
Here, we simulated the evolution of all three classes of nano-agents
in three tumour scenarios: (1) Non-evolvable heterogeneous tumour
(cancer cells cannot mutate and 10% of cancer cells are partially
resistant), (2) Evolvable homogeneous tumour (cancer cells can mutate
and do not have resistance modifiers) and (3) Evolvable heterogeneous
tumour (cancer cells can mutate and 10% of the cells are partially
resistant). In the model, mutations of cancer cells change their pheno-
type, so they can evade recognition by NA. Therefore, the first scenario
represents a tumour with only intrinsic resistance, the second scenario
is a homogeneous tumour with only acquired resistance, while the third
scenario represents a more realistic scenario of a tumour with both
intrinsic and acquired resistance.
In all of these more challenging scenarios, fully evolvable NA𝐸
agents show similar efficacy. Within the first 400−500 generations they
learn to recognize and kill all cancer cells (Fig. 3b,c,d) while keeping
the healthy cells mostly intact (as shown in Fig. 4).
In the non-evolvable scenario, NA0 agents behave similarly to NA𝐸
agents. The only difference is that NA0 agents reach the fitness peak
slightly earlier than NA𝐸 agents, regardless of the initial percentage of
resistant tumour cells (Fig. 5). The reason for that is the functioning of
the learning algorithm in NA𝐸 agents. NA0 agents do not learn during
the simulation, so they immediately proceed with killing cancer cells.
In contrast, evolvable NA𝐸 agents have limited memory (maximum 3)
and they can ‘‘forget’’ old data. Therefore, in order to kill all cancer
cells, some of NA𝐸 agents need to re-learn to recognize diverse cancer
cells. This process of forgetting and re-learning generates a time lag,
that disappears when we increase maximum memory capacity to 10
(data not shown).
BioSystems 199 (2021) 104290I. Balaz et al.Fig. 2. Â test results for up to 1000-step simulation runs. For each sample size we calculated Â test after 50, 100, 250, 300, 500 and 1000 time steps (black dots).Fig. 3. Fitness evolution of NA0, NA𝐺 and NA𝐸 agents for different tumour scenarios. Heterogeneous tumours have 10% of resistant cells.t
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In evolvable homogeneous and heterogeneous tumour scenarios,
NA𝐸 agents show their full potential compared to NA0 and NA𝐺 agents.
In both evolvable scenarios, the tumour managed to escape NA0 agents,
through evolution, and become composed entirely of mutated cells (for
heterogeneous example see Fig. 6a). When treated with NA𝐸 and NA𝐺
agents, this is not the case. The percent of mutated tumour cells starts
to rise at the beginning of the simulation but then rapidly declines.
NA𝐺 agents can, right away, without having to memorize and recognize
them, eliminate all cancer cells, so the maximum reached percentage
of mutated cells is quite low. However, when both (homogeneous and
heterogeneous) tumours are treated with NA𝐸 agents, the number of
mutated cells reaches 40% and their peak is at about 100 time steps
later than in the case of NA𝐺 agents. As with the lag in reaching4
fitness peak in a non-evolvable tumour scenario, the reason lies inthe learning process. In contrast to NA𝐺 agents, in order to eliminate
emerging mutated cancer cells, NA𝐸 agents have to continuously learn,
memorize, and eventually re-learn the environment. Therefore, in this
scenario, NA𝐸 agents are somewhat slower in eliminating tumour cells
han NA𝐺 agents.
If in the evolvable heterogeneous tumour we observe intrinsic tu-
our resistance, represented by heterogeneity in the resistance of the
ells, we can see a similar trend for NA𝐸 and NA𝐺 agents (Fig. 6b).
The percentage of resistant cells first grows, because of the selective
pressure: NAs can more easily kill non-resistant cells, so they are the
first to be eliminated. This leaves the empty space for the more resistant
cells to replicate. With NA𝐸 and NA𝐺 treatment, the percentage of
resistant tumour cells goes up to approximately 40%, whereas the peak
𝐺and duration of tumour resistance are much smaller for NA treatment.
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Fig. 4. Efficacy of all three classes of nano-agents in evolvable heterogeneous tumour scenario. (a) number of cancer cells as a function of time. (b) number of healthy cells as a
function of time. (c) relation between the number of healthy cells and the number of cancer cells.Fig. 5. Fitness evolution of NA𝐸 and NA0 agents for non-evolvable heterogeneous tumour. Percent of resistance indicate initial number of cancer cells with resistance modifiers.gain, NA𝐺 agents do not need to spend time learning to adapt to
newly emerging resistant cancer cells, as is the case for NA𝐸 agents.
Nevertheless, NA𝐸 agents are very efficient in learning to recognize
new cancer cell phenotypes (Fig. 6c) needing less than 100 generations
to be able to recognize almost all emerging phenotypes. In the case of
NA0 treatment, only a fraction of initially recognized cancer cells will
be eliminated while the rest of the tumour will escape recognition via
phenotype mutations. Non-resistant cells have a higher probability to
be among firstly eliminated cells so the percentage of resistant cells5
only slightly increases and then remains constant.To conclude this section, we would like to emphasize that even
though NA𝐺 agents are fastest to eliminate the entire tumour (Fig. 4a)
and to deal with mutated and resistant cancer cells, their efficacy
is consistently the worst, primarily because they end up killing both
tumour and healthy cells (Fig. 4b). We tested several scenarios of
NA𝐺 ’s bias towards killing tumour cells by increasing the probability
of attacking tumour cells and decreasing the probability of attacking
healthy cells (Fig. 7). As expected, higher bias towards cancer cells
leads to a sharper increase in fitness, but eventually, due to the killing
of healthy cells, fitness converges towards zero in all tested cases.
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Fig. 6. Behaviour of evolvable heterogeneous tumour in different treatment regimes. (a) Temporal evolution of the ratio of phenotype mutated tumour cell and the total number
f tumour cells. (b) Temporal evolution of the ratio of resistant tumour cell and the total number of tumour cells. (c) Tumour coverage is the ratio of the number of tumour cell
ypes that the population of nano-agents can recognize and the total number of tumour cell types. NA𝐺 agents are not shown because they can recognize all cells so their coverage
would always be 1.Fig. 7. (a) Fitness and (b) tumour mutation response when treated with NA𝐺 with different biases towards cancer cells. In addition to the default one (specified in Table 1 and
indicated here as NA𝐺 07/05) for which 𝑝𝑎, 𝑝𝑖, 𝑝𝑘 and 𝑝𝑠𝑑 values are 0.7 (when attacking cancer cells) and 0.5 (when attacking healthy cells), we also tested NA𝐺 08/04 and NA𝐺
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Growing tumour To test whether the growing tumour will signif-
cantly change the outcome of treatments with NAs, we simulated a
eterogeneous, evolvable tumour with the following growth rates: 0.01,
.005 , and 0.001. As expected, for higher growth rates, NAs need
ore time to eliminate all cancer cells. For the growth rate of 0.001,
A𝐸 agents need about 500 generations (compared to approximately
00 generations for the non-growing tumour — see Fig. 4a), while for
he growth rate of 0.005 time needed is much longer (almost 5000
enerations). Only in the case of the fastest tested growth rate (0.01),
fter the initial sharp decline, the population of remaining cancer cells
tarts to grow (Fig. 8a) and eventually became larger than the original
umour.
For all tested growth rates, tumour resistance continuously grows
as an example see Fig. 8b for the scenario with the growth rate =6
e
.01), mostly as a result of 50 fold increase of disassociation probability.
his is in contrast with a non-growing tumour where probabilities of
ssociation, disassociation, and internalization remain constant during
he simulation period. Such discrepancy is a result of different survival
trategies. In a non-growing tumour, the number of cells is fixed, so
here is no possibility to select for any property that will proliferate,
volve, and became dominant through generations. However, in a
rowing tumour, the fact that cells can divide gives exactly that oppor-
unity to more resistant cells. Apparently, the property of cancer cells
hat is mostly favoured is the disassociation probability (probability of
nternalization is mostly constant, while the probability of association
lightly increases).
At the same time, the percentage of mutated cancer cells shows the
xpected trend: in NA0 treatment tumour population gradually escape
BioSystems 199 (2021) 104290I. Balaz et al.Fig. 8. Behaviour of evolvable heterogeneous growing tumour in different treatment regimes (growth rate = 0.01). (a) Temporal evolution of the total number of cancer cells.
(b) Temporal evolution of tumour resistance, defined as a sum of resistance effect of all living cancer cells. (c) Temporal evolution of the ratio of phenotype mutated tumour cell
and the total number of tumour cells.i
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Fig. 9. Summary scheme of efficacy of all three NA classes simulated in this paper.
CC — cancer cells; HC — healthy cells.
treatment by mutating, while open-ended evolution of NA𝐸 agents can
continuously track down newly emerging tumour mutations and keeps
them under control (Fig. 8c).
4. Concluding remarks
In the model presented here, our primary aim was to demonstrate
that open-ended evolution of NA𝐸 agents leads to the emergence of
adaptive and combinatorial therapy that can eliminate a heteroge-
neous, evolvable tumour, which is one of the main problems in today’s
oncological clinical practice (Vasan et al., 2019). Our main finding is
that, despite the tumour’s phenotypic plasticity, NA𝐸 agents are flexible
enough to respond to such changes and successfully track down and
kill all cancer cells. Their efficacy of killing cancer cells is somewhat
lower compared with NA𝐺 agents (Fig. 9), but at the same time, NA𝐺
agents kill most of the healthy cells making extensive damage to a
patient. During simulations, in both the growing and the non-growing
tumour, initially homogeneous NA𝐸 population starts to diverge and
became increasingly heterogeneous as nano-agents become specialized
for recognizing each newly emerged type of cancer cells, while at the
same time optimizing their own parameters needed for eliminating the7
C
tumour. For the first 300 generations Pearson’s correlation between
NA𝐸 population heterogeneity and the percent of mutated cancer cells
s 0.77. After that, the percentage of mutated cancer cells starts to
ecline, while NA𝐸 population heterogeneity remains stable until the
nd of the simulation period (data not shown).
However, the model presented here lacks many of the details nec-
ssary for the computational platform that could be used in real-world
esearch and clinical practice. In modelling the influence and impact
f nanoparticles on cancer progression, multiple scales have to be con-
idered: molecular-scale interactions of individual nanoparticles with
rugs and their environment; cellular scale interactions of numerous
anoparticles with the cell environment as well as the macroscopic
cale which describes details of cancer cells, their mutual interactions,
nd their interactions with the environment (Bellomo et al., 2003). Fur-
hermore, in order to apply this finding in a real-world setting, both the
imulated agents and the simulated tumour must be based on realistic
arameters derived from the nanoparticle’s physicochemical properties
nd tumour’s physiology. Physicochemical properties of nanoparticles
dd complexity associated with pharmacodynamics, pharmacokinetics,
umour accumulation, and biodistribution. Also, when nanoparticles
nter the bloodstream, they encounter several transport barriers such as
he formation of the protein corona, vascular transport, extravasation,
ndocytosis, and RES uptake. Each of these barriers is a considerable
ndividual challenge (Stillman et al., 2020). Therefore, nanoparticles
ust be designed in such a way to overcome several (if not all) of them
o reach maximum efficacy.
As emphasized in the Introduction, the versatility of NPs gives a
ide range of customization possibilities. However, it also leads to
rich design space that is difficult to optimize and is computation-
lly expensive. In this paper, using a relatively simple model, we
emonstrated that open-ended evolution coupled with multidimen-
ional optimization can lead to the emergence of successful virtual
nti-cancer therapies. However, the computational cost of simulations
ill become unmanageable if we try to implement all aspects men-
ioned above. Therefore, we intend to further develop this model as
part of a more complex pipeline that will be composed of sev-
ral modules. The pipeline under development consists of three main
odules: an open-ended evolution for the automated virtual design
f treatments (this model), simulation of a virtual tumour (Physi-
ell (Ghaffarizadeh et al., 2018)), and simulation of nanoparticle–cell
BioSystems 199 (2021) 104290I. Balaz et al.
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interactions (STEPS (Hepburn et al., 2012)). In our next steps we will
further refine this model by adding three main features:
• realistic mapping between properties of simulated nano-agents
and real chemical counterparts (e.g. setting up speeds 𝑝𝑎, 𝑝𝑑 , 𝑝𝑖,
𝑝𝑘 and 𝑝𝑠𝑑 based on measured chemical properties);
• automated evaluation of evolved treatment strategies;
• input/output interface between this model and tumour and cellu-
lar simulators so that evolved virtual treatments could be easily
tested in a more realistic setting.
How such added complexity will influence the evolutionary emer-
ence of combinatorial therapies will be investigated in our future
ork.
As a final note, we would like to emphasize that in generalized
erms, the approach developed here can be applied to many prob-
ems whose structure and outcomes can change over time. Besides
ncology, a similar approach could work in designing treatment for
nfectious diseases where bacteria or viruses can evolve, develop resis-
ance to treatments, and form heterogeneous populations. Outside of
he medical field, an example of a possible application is designing a
lan of social policy actions where a given segment of society is also
hangeable and heterogeneous. However, to translate the approach we
utlined here to any of the new problem domains would require careful
onsideration of constraints and structure of that domain. That is also
task for our future work.
RediT authorship contribution statement
Igor Balaz: Conceptualization of this study, Writing, Methodology,
nalysis of results, Data interpretation. Tara Petrić: Software develop-
ent, Data curation, Data interpretation. Marina Kovacevic: Analysis
f results, Data interpretation. Michail-Antisthenis Tsompanas: Anal-
sis of results, Data interpretation. Namid Stillman: Analysis of results,
ata interpretation.
eclaration of competing interest
The authors declare that they have no known competing finan-
ial interests or personal relationships that could have appeared to
nfluence the work reported in this paper.
eferences
lden, K., Read, M., Timmis, J., Andrews, P., Veiga-Fernandes, H., Coles, M., 2013.
Spartan: A comprehensive tool for understanding uncertainty in simulations of
biological systems. PLoS Comput. Biol. 9, e1002916.
ellomo, N., De Angelis, E., Preziosis, L., 2003. Review article: Multiscale modeling and
mathematical problems related to tumor evolution and medical therapy. J. Theor.
Med. 5, 111–136.
lanco, E., Shen, H., Ferrari, M., 2015. Principles of nanoparticle design for overcoming
biological barriers to drug delivery. Nature Biotechnol. 33, 941–951.
ozic, I., Reiter, J., Allen, B., Antal, T., et al., 2013. Evolutionary dynamics of cancer
in response to targeted combination therapy. eLIFE 2, e00747.
hen, S.h., Lahav, G., 2016. Two is better than one; toward a rational design of
combinatorial therapy. Curr. Opin. Struct. Biol. 41, 145–150.8
anciullino, R., Ciccolini, J., Milano, G., 2013. Challenges, expectations and limits for
nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs.
Crit. Rev. Oncol./Hematol. 88, 504–513.
ener, P., de Sous Rafael, D., Fernandez, Y., Ortega, J., Arango, D., Abasolo, I.,
Videira, M., Schwartz, S., 2016. Cancer stem cells and personalized cancer
nanomedicine. Nanomedicine 11, 307–320.
haffarizadeh, A., Heiland, R., Friedman, S.H., Mumenthaler, S.M., Macklin, P., 2018.
Physicell: an open source physics-based cell simulator for 3-d multicellular systems.
PLoS Comput. Biol. 14, e1005991.
auert, S., Berman, S., Nagpal, R., Bhatia, S., 2013. A computational framework for
identifying design guidelines to increase the penetration of targeted nanoparticles
into tumors. Nano Today 8, 566–576.
epburn, I., Chen, W., Wils, S., De Schutter, E., 2012. Steps: efficient simulation of
stochastic reaction–diffusion models in realistic morphologies. BMC Syst. Biol. 6,
1–19.
olohan, C., Van Schaeybroeck, S., Longley, D., Johnston, P., 2013. Cancer drug
resistance: and evolving paradigm. Nature Rev. Cancer 13, 714–726.
u, Z., Sun, R., Curtis, C., 2017. A population genetics perspective on the determinants
of intra-tumour heterogeneity. Biochim. Biophys. Acta 1867, 109–126.
arev, G., Novozhilov, A., Koonin, E., 2006. Mathematical modeling of tumor therapy
with oncolytic viruses: effects of parametric heterogeneity on cell dynamics. Nature
Rev. Mater. 1, 30.
urtova, A., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S., Chen, F.,
Roh, T., Lay, E., Ho, P., Chan, K., 2014. Blocking pge2-induced tumour repopulation
abrogates bladder cancer chemoresistance. Nature 517, 209–213.
aeda, H., Nakamura, H., Fang, J., 2013. The epr effect for macromolecular drug
delivery to solid tumors: Improvement of tumor uptake, lowering of systemic
toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65, 71–79.
asad, D., Kazil, J., 2015. Mesa: An agent-based modeling framework. In: Huff, K.,
Bergstra, J. (Eds.), Proceedings of the 14th Python in Science Conference. pp.
51–58. http://dx.doi.org/10.25080/Majora-7b98e3ed-009.
attabiraman, D., Weinberg, R., 2014. Tackling the cancer stem cells - what challenges
do they pose. Nat. Rev. Drug Discov. 13, 497–512.
reen, R., Bull, L., Adamatzky, A., 2019. Towards and evolvable cancer treatment
simulator. BioSystems 182, 1–7.
ead, M., Andrews, P., Timmis, J., Kumar, V., 2012. Techniques for grounding agent-
based simulations in the real domain: a case study in experimental autoimmune
encephalomyelitis. Math. Comput. Model. Dyn. Syst. 18, 67–86.
ockne, R., Hawking-Daarud, A., Swanson, K., Sluka, J., Glazier, J., Macklin, P., Hor-
muth II, D., Jarett, A., Lima, E., Tinsle Oden, J., Biros, G., Yankeelov, T., Curtius, K.,
al Bakir, I., Wodarz, D., Komarova, N., Bordyuh, L., Rabadan, R., Finley, S.,
Enderling, H., Caudell, J., Moros, E., Anderson, A.R.A.G., Kaznatcheev, A., Jeav-
ons, P., Krishnan, N., Pelesko, J., Wadhwa, R., Yoon, N., Nichol, D., Marusyk, A.,
Hinczewski, M., Scott, J., 2019. The 2019 mathematical oncology roadmap. Phys.
Biol. 16, 041005, 1–47.
haffer, S., Dunagin, M., Torborg, S., Torre, E., et al., 2017. Rare cell variability and
drug-induced reprogramming as a mode of cancer drug resistance. Nature 546,
431–435.
tillman, N., Kovacevic, M., Balaz, I., Hauert, S., 2020. In silico modelling of cancer
nanomedicine, across scales and transport barriers. npj Comput. Mater. 6 (92).
aylor, T., 2019. Evolutionary innovations and where to find them: Routes to
open-ended evolution in natural and artificial systems. Artif. Life 25, 207–224.
sompanas, M.A., Bull, L., Adamatzky, A., Balaz, I., 2020. Novelty search employed into
the development of cancer treatment simulations. Inform. Med. Unlocked 100347.
argha, A., Delaney, H., 2000. A critique and improvement of the cl common language
effect size statistics of mcgraw and wong. J. Educ. Behav. Stat. 25, 101–132.
asan, N., Baselga, J., Hyman, D., 2019. A view on drug resistance in cancer. Nature
575, 299–309.
icki, A., Witzigmann, D., Balasubramanian, V., Huwyler, J., 2015. Nanomedicine
in cancer therapy: Challenges, opportunities, and clinical applications. J. Control.
Release 28, 138–157.
ilhelm, S., Tavares, A., Dai, Q., Ohta, S., Audet, J., Dvorak, H., Chan, C., 2016.
Analysis of nanoparticle delivery to tumours. Nature Rev. Mater. 1–12, 16014, 1–.
